Roxi-Ai

Roxi-AI is redefining how biopharma evaluates therapeutic assets. Our AI-powered platform predicts the likelihood of success for drugs in development by synthesizing data from clinical trials, regulatory filings, scientific literature, and real-world news. The result: standardized, objective risk assessments across scientific, clinical, regulatory, and commercial dimensions. Pharma business development teams use Roxi-AI to identify high-potential assets and de-risk in-licensing decisions. Investors rely on our insights to benchmark portfolios, validate diligence assumptions, and predict value inflection points with confidence. With over 90% predictive accuracy in retrospective testing, Roxi-AI transforms uncertainty into data-driven foresight. Our mission is simple: help the biopharma ecosystem make faster, smarter, and more confident investment and development decisions—because every good decision accelerates innovation that patients are waiting for.